FairJourney Biologics SA (FJB) and IONTAS Limited (IONTAS), leaders in the discovery and optimization of VHH and all-human antibodies, announced today that they have signed an antibody discovery agreement with Pandion Therapeutics (Pandion). The collaboration will utilize the proprietary FJB and IONTAS antibody libraries and technology platforms to explore new therapeutic targets for autoimmune and inflammatory diseases.
FairJourney Biologics Laboratory
Pandion focuses on the development of innovative modular therapies using the TALON ™ drug design and discovery platform (Therapeutic Autoimmune reguLatOry proteiN). TALON operator units are based on immunomodulatory molecules that act as regulatory control points in the immune system. In combination with a special tissue targeting group, the operators create new bifunctional molecules to treat autoimmune and inflammatory diseases.
Under the terms of the agreement, Pandion will have access to the new libraries and platform technologies provided by FJB and IONTAS. A dedicated FJB / IONTAS FTE will be commissioned to discover different frameworks of new connecting targets for use within the TALON platform. The agreement expands an existing relationship between the companies and enables Pandion to use a standard phage screen or mammalian screen as engines to detect next-generation antibodies.
Our teams have gained significant experience in detecting antibodies for use in creating mono-specific and bi-specific therapies. We now have a pipeline unknown therapeutic collaborations close to clinical research. We look forward to continuing our relationship with Pandion and applying our experience and expertise to create a different set of antibodies for further study.
Dr. António Parada, CEO of FairJourney Biologics and IONTAS
The TALON platform utilizes natural immune regulatory mechanisms to rebalance immune responses and ultimately advance the discovery of new therapies for autoimmune and inflammatory diseases. The experience in detecting antibodies shared by FJB and IONTAS, together with the unique library of binding targets, makes them ideal partners as we focus on the successful progress of these therapeutic treatments in patients in need. “
Dr. Hussam Shaheen, Director of Antibody Detection and Engineering at Pandion Therapeutics